Innate Pharma (IPHA) Other Non-Current Assets (2017 - 2025)
Innate Pharma's (IPHA) quarterly Other Non-Current Assets came in at $1.1 million in Q4 2025, up 79.41% YoY from $614442.4 in Q4 2024, and up 68.78% on a QoQ basis from $653140.7 in Q2 2025.
Innate Pharma (IPHA) Other Non-Current Assets (2017 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 9 years of Other Non-Current Assets data on file, last reported at $1.1 million in Q4 2025.
- Quarterly Other Non-Current Assets rose 79.41% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 million (up 79.41% YoY) and the FY2025 annual result came in at $1.1 million, up 79.41% from the prior year.
- Other Non-Current Assets rose to $1.1 million in Q4 2025, from $653140.7 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $1.1 million in Q4 2025 to a low of $91535.4 in Q2 2024.
- A 5-year average of $338193.5 and a median of $164149.6 in 2021 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2021 — Other Non-Current Assets plunged 99.82% — and 2025, when it jumped 613.54%.
- Tracing IPHA's Other Non-Current Assets over 5 years: stood at $169307.7 in 2021, then slipped by 10.21% to $152016.9 in 2022, then plunged by 38.42% to $93606.8 in 2023, then surged by 556.41% to $614442.4 in 2024, then jumped by 79.41% to $1.1 million in 2025.
- The last three Other Non-Current Assets figures came in at $1.1 million (Q4 2025), $653140.7 (Q2 2025), and $614442.4 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - | 1.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.10 Mn |
| Jun 30, 2025 | 653,140.74 |
| Dec 31, 2024 | 614,442.36 |
| Jun 30, 2024 | 91,535.44 |
| Dec 31, 2023 | 93,606.77 |
| Jun 30, 2023 | 93,647.50 |
| Dec 31, 2022 | 152,016.86 |
| Jun 30, 2022 | 158,991.45 |
| Dec 31, 2021 | 169,307.70 |
| Jun 30, 2021 | 252,897.00 |
| Dec 31, 2020 | 175,266.61 |
| Jun 30, 2020 | 141.00 Mn |
| Dec 31, 2019 | 98,513.00 |
| Dec 31, 2018 | 98,160.09 |
| Dec 31, 2017 | 130,695.01 |